Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
Corvus Pharmaceuticals (NASDAQ: CRVS) will present final data from its Phase 1/1b trial of soquelitinib in relapsed/refractory T cell lymphomas at the 67th American Society of Hematology Annual Meeting & Exposition.
The oral presentation is scheduled for December 8, 2025, Session 625 (T Cell, NK Cell, or NK/T Cell Lymphomas), with a presentation slot from 11:15 AM–11:30 AM (session 10:30 AM–12:00 PM). Publication number is 778; the title reports final Phase 1 results for soquelitinib (SQL), an ITK inhibitor for R/R T cell lymphomas.
Corvus Pharmaceuticals (NASDAQ: CRVS) presenterà i dati finali dello studio di Fase 1/1b di soquelitinib nei linfomi a cellule T in recidiva/refrattari, all'67ª riunione annuale ed esposizione dell'American Society of Hematology.
La presentazione orale è prevista per 8 dicembre 2025, Sessione 625 (linfomi T, NK o NK/T), con uno slot di presentazione dalle 11:15–11:30 (sessione dalle 10:30 alle 12:00). Il numero di pubblicazione è 778; il titolo riporta i risultati finali di Fase 1 per soquelitinib (SQL), un inibitore ITK per linfomi T recidivanti/refrattari.
Corvus Pharmaceuticals (NASDAQ: CRVS) presentará datos finales de su ensayo de Fase 1/1b de soquelitinib en linfomas de células T en recaída/refractarios en la 67.ª Reunión Anual y Exposición de la American Society of Hematology.
La presentación oral está programada para 8 de diciembre de 2025, Sesión 625 (linfomas de células T, NK o NK/T), con una franja de presentación de 11:15–11:30 (sesión de 10:30 a 12:00). El número de publicación es 778; el título reporta resultados finales de Fase 1 para soquelitinib (SQL), un inhibidor ITK para linfomas de células T en recaída/refractarios.
Corvus Pharmaceuticals (NASDAQ: CRVS)는 재발성/난치성 T 세포 림프종에서 soquelitinib의 1상/1b상 최종 데이터를 제67회 미국 혈액학회 연례 회의 및 전시회에서 발표합니다.
구두 발표는 2025년 12월 8일에 예정되어 있으며, 세션 625( T 세포, NK 세포 또는 NK/T 세포 림프종), 발표 시간은 11:15–11:30이며(세션은 10:30–12:00 사이) 발표 번호는 778입니다. 제목은 soquelitinib(SQL)의 1상 최종 결과를 보고하며, 이는 재발/난치성 T 세포 림프종을 위한 ITK 억제제입니다.
Corvus Pharmaceuticals (NASDAQ: CRVS) présentera les données finales de son essai de Phase 1/1b de soquelitinib dans les lymphomes T à rechute/réfractaires lors de la 67e réunion annuelle et exposition de l'American Society of Hematology.
La présentation orale est prévue pour le 8 décembre 2025, Session 625 (lymphomes T, NK ou NK/T), avec une plage de présentation de 11:15–11:30 (session de 10:30 à 12:00). Le numéro de publication est 778; le titre rapporte les résultats finaux de la Phase 1 pour soquelitinib (SQL), un inhibiteur de l'ITK pour les lymphomes T en rechute/réfractaires.
Corvus Pharmaceuticals (NASDAQ: CRVS) wird die endgültigen Daten aus seiner Phase-1/1b-Studie von soquelitinib bei rezidivierenden/refraktären T‑Zell-Lymphomen auf der 67. Jahrestagung und Ausstellung der American Society of Hematology vorstellen.
Die mündliche Präsentation ist für 8. Dezember 2025 vorgesehen, Sitzung 625 (T‑Zell-, NK‑Zell- oder NK/T‑Zell-Lymphome), mit einem Präsentationsfenster von 11:15–11:30 (Sitzung 10:30–12:00 Uhr). Veröffentlichungsnummer ist 778; der Titel berichtet über die Endergebnisse der Phase 1 für soquelitinib (SQL), einem ITK‑Inhibitor für RR/T‑Zell-Lymphome.
Corvus Pharmaceuticals (NASDAQ: CRVS) ستقدم البيانات النهائية من تجربة المرحلة 1/1b لـ soquelitinib في الأورام اللمفاوية من نوع T المتكررة/المقاومة في الاجتماع السنوي والمعرض للجمعية الأمريكية للأمراض الدمويّة الـ 67.
المحاضرة الشفوية مقررة في 8 ديسمبر 2025، الجلسة 625 (سرطانات الخلايا T، NK، أو NK/T)، مع فتحة عرض من 11:15 صباحاً–11:30 صباحاً (الجلسة من 10:30 صباحاً حتى 12:00 ظهراً). رقم النشر هو 778; العنوان يذكر النتائج النهائية للمرحلة 1 لـ soquelitinib (SQL)، وهو مثبّت ITK لعلاج سرطانات خلايا T المعاودة/المقاوَمة.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place December 6-9, 2025 in Orlando, FL.
Details regarding the oral presentation are as follows:
Session Name: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Novel agents or therapeutic approaches in T-cell Lymphoma
Session Date: December 8, 2025
Session Time: 10:30 AM - 12:00 PM
Presentation Time: 11:15 AM - 11:30 AM
Publication Number: 778
Title: Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is now in a registration Phase 3 clinical trial for relapsed/refractory T cell lymphoma and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When will Corvus Pharmaceuticals (CRVS) present soquelitinib Phase 1/1b final data at ASH 2025?
What is the ASH 2025 session and publication number for CRVS soquelitinib data?
What will Corvus (CRVS) present about soquelitinib at ASH 2025?
Where and when is the 67th ASH Annual Meeting where CRVS will present?
How long is the Corvus (CRVS) presentation slot for soquelitinib at ASH?
What is soquelitinib (SQL) as described in the ASH 2025 listing for CRVS?
